Ovarian cancer: Should we be managing patients with good and bad prognostic factors in the same manner?

Annals of Oncology

Volumn 10, Issue SUPPL. 1, 1999, Pages

  Eisenhauer, E A ^a   Gore, M ^b   Neijt, J P ^c  

^a QUEEN S UNIVERSITY   (Canada)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Molecular markers; Ovarian cancer; Predictive factors; Prognostic factors

Indexed keywords

ALTRETAMINE; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL;

APOPTOSIS; CANCER PATIENT; CANCER SURVIVAL; CONFERENCE PAPER; HUMAN; MULTIVARIATE ANALYSIS; OVARY CANCER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; TREATMENT PLANNING;

EID: 0032961991     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0923-7534(20)31478-2     Document Type: Conference Paper

References (54)

1. Gasparini G, Pozza F, Harris AL. Evaluating the potential usefulness of new prognostSic and predictive indicators in node-negative breast cancer. J Natl Cancer Inst 1993; 85: 1206-19.
2. Kodama S, Yanaka K, Tokunaga A, at al. Multivariate analysis of prognostic factors in patients with ovarian cancer stage I and II. Int J Gynecol Obstet 1997; 56: 147-53.
3. Ahmed FY, Wiltshaw E, A'Heam RP, et al. Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. J Clin Oncol 1996; 14: 2968-75.
4. Schueler JA, Trimbos JB, van der Burg M, et al. DNA index reflects the biological behavior of ovarian carcinoma stage I-IIa. Gynecol Oncol 1996; 62: 59-66.
5. Nagele F, Petru E, Medl M et al. Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1995; 86: 259-64.
6. Trope C, Kaern J, Vergote I at al. Randomized trial on adjuvant carboplatin versus no treatment in stage I high risk ovarian cancer by the Nordic Ovarian Cancer Study Group (NOCOVA). Proc Am Soc Clin Oncol 1997; 16: 1260 (Abstr).
7. Geisler JP, Geisler HE, Wiemann MC et al. Quantification of p53 in epithelial ovarian cancer. Gynecol Oncol 1997; 66: 435-8.
8. Scambia G, Masciullo V, Benedetti Panici P, et al. Prognostic significance of ras/p21 alterations in human ovarian cancer. Br J Cancer 1997; 75: 1547-53.
9. Colozza M, Mosconi AM, Gori S et al. Long-term results in patients with advanced epithelial ovarian carcinoma treated with a combination of cisplatin, doxorubicin and cyclophosphamide. Am J Clin Oncol 1997; 20: 522-6.
10. Marx D, Meden H, Brune T et al. Mib-1 evaluated proliferative activity in ovarian cancer with respect to prognostic significance. Anti-cancer Res 1997; 17: 775-80.
11. Brinkhuis M, Baak JP, Meijer GA et al. Value of quantitative pathological variables as prognostic factors in advanced ovarian cancer. J Clin Path 1996; 49: 142-8.
12. Klemi PJ, Pylkkanen L, Kiiholma P, et al. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 1995; 76: 1201-8.
13. Meden H, Marx D, Raab T et al. EGF-R and overexpression of the oncogene c-erbB-2 in ovarian cancer: immunohistochemical findings and prognostic value. J Obstet Gynecol 1995; 21: 167-78.
14. Warwick J, Kehoe S, Earl H et al. Long-term follow-up of patients with advanced ovarian cancer treated in randomized clinical trials. Br J Cancer 1995; 72: 1513-7.
15. Van Diest PJ, Zevering JP, Zevering LC et al. Prognostic value of microvessel quantitation in cisplatin treated FIGO 3 and 4 ovarian cancer. Pathol Res Practice 1995; 191: 25-30.
16. Scambia G, Benedetti-Panici P, Ferrandina G et al. Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy. Br J Cancer 1995; 72: 361-6.
17. Fajac A, Benard J, Lhomme C, et al. C-erbB2 gene amplification and protein expression in ovarian epithelial tumors: evaluation of their respective prognostic significance by multivariate analysis. Int J Cancer 1995; 64: 146-51.
18. Felip E, del Campo JM, Rubio D et al. Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy. Cancer 1995; 75: 2147-52.
19. Makar AP, Baekelandt M, Trope CG et al. The prognostic significance of residual disease, FIGO substage, tumor histology and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol 1995; 56: 175-80.
20. Levesque MA, Katsaros D, Yu H, et al. Mutant p53 is associated with poor outcome in patients with well or moderately differentiated ovarian cancer. Cancer 1995; 75: 1327-38.
21. Bruzzone M, Gadduci A, Brunetti I, et al. Prognostic factors affecting long-term survival of advanced ovarian cancer (AOC) patients (pts): univariate and multivariate analysis at 12 years of follow-up. Proc Am Soc Clin Oncol 1995; 14: 812 (Abstr).
22. Van Dam PA, Vergote IB, Lowe DG, et al. Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I and epidermal growth factor receptor in ovarian carcinoma. J Clin Path 1994; 47: 914-9.
23. Hartmann LC, Podratz KC, Kleeney GL, et al. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol 1994; 12: 64-9.
24. Khoo SK, Battistutta D, Hurst T, et al. The prognostic value of clinical, pathological, and biologic parameters in ovarian cancer. Cancer 1993; 72: 531-7.
25. Ferrandina G, Scambia G, Damia G et al. Glutathione S-transferase activity in epithelial ovarian cancer: Association with response to chemotherapy and disease outcome. Ann Oncol 1997; 8: 343-50.
26. Parker D, Bradley C, Bogle SM et al. Serum albumin and CA125 are powerful predictors of survival in epithelial ovarian cancer. Br J Obstet Gynecol 1994; 101: 808-93.
27. Tanner B, Hengstler JG, Laubscher S, et al. mdm 2 mRNA expression is associated with survival in ovarian cancer. Int J Cancer 1997; 74: 438-42.
28. Izquierdo MA, van der Zee AGJ, Vermorken JB, et al. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst 1995; 87: 1230-7.
29. Hollingsworth HC, Kohn EC, Steinberg SM, et al. Tumor angiogenesis in advanced stage ovarian Carcinoma. Am J Path 1995; 146: 33-41.
30. Kehoe S, Powell J, Wilson S, et al. The influence of operating surgeon's specialisation on patient survival in ovarian carcinoma. Br J Cancer 1994 70: 1015-7.
31. Alberst DS, Dahlberg S, Green SJ, et al. Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin cyclophosphamide in stages III (suboptimal) and IV ovarian cancer. Cancer 1993; 71: 618-27.
32. Berchuck A, Kamel A, Whitaker R, et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990; 50: 4087-91.
33. Van der Zee AGJ, Hollema H, Suurmeijer AJH, et al. Value of p-glycoprotein, glutathione s-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 1995; 13: 70-78.
34. Dong Y, Walsh MD, McGuckin MA, et al Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer. Int J Cancer 1997; 74: 407-15.
35. Rubin SC, Finstad CL, Wong GY, et al. Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis. Am J Obstet Gynecol 1993; 168: 162-9.
36. Tai Y-T, Lee S, Niloff E, et al. BAX protein expression and clinical outcome in epithelial ovarian cancer J Clin Oncol 1998; 16: 2583-90.
37. Nguyen H, Averette H, Hoskins W, et al. National survey of ovarian carcinoma V. The impact of physicians speciality on patients survival. Cancer 1993; 72: 3663-70.
38. Advanced ovarian cancer trials group. Chemotherapy in advanced ovarian cancer: An overview of randomized clinical trials. Brit Med J 1991; 303: 884-93.
39. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. New Engl J Med 1996; 334: 1-6.
40. Stuart G, Bertelsen K, Mangioni C, et al: Updated analysis shows a highly significant improved overall survival (OS) for cisplatin-paclitaxel as first-line treatment of advanced ovarian cancer: mature results of the EORTC-GCCG, NOCOVA, NCIC CTG and Scottish Intergroup Trial. Proc Am Soc Clin Oncol 1998; 17: 361a (Abstr).
41. Vermorken JB. Pecorelli S. Clinical trials in patients with epithelial ovarian cancer: past, present and future. Eur J Surgical Oncol 1996; 22 (5): 455-66.
42. Yedema CA, Kenemans P, Voorhorst F, et al. CA 125 half life in ovarian cancer: a multivariate survival analysis. Br J Cancer 1993; 67: 1361-7.
43. Romagnolo C, Gadducci A, Zola P, et al. Serum half-life of CA-125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study. Anticancer Res 1995; 15 (5A): 1765-6. (Abstr)
44. Fisken J, Leonard RC, Stewart M, et al. The prognostic value of early CA 125 serum assay in epithelial ovarian carcinoma. Br J Cancer 1993; 68: 140-5.
45. Liu PY, Alberts DS, Federico M, et al. CA-125 concentration 8 weeks after treatment initiation independently predicts survival in patients with advanced epithelial ovarian cancer: a Southwest Oncology Group (SWOG) study. Proc Am Soc Clin Oncol 1995; 14: 735 (Abstr).
46. Copeland LJ Vaccarello L Lewandowski GS. Second-look laparotomy in epithelial ovarian cancer. Obst Gynecol Clin North Am 1994; 21 (1): 155-66.
47. Van der Burg ME, van Lent M, Buyse M et al. Th effect of debulking surgery after induction chemotherapy on the prognosis in advanced ovarian cancer. New Engl J Med 1995; 332: 629-34.
48. Blackledge G, Lawton F, Redman C, Kelly K. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 1989; 59: 650-3.
49. Gore ME, Fryatt I, Wiltshaw E, Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 1990; 36: 207-11.
50. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991; 9: 389-93.
51. Eisenhauer EA, Vermorken JB, Van Glabbeke M: Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: an analysis of 704 patients. Ann Oncol 1997; 8: 963-8.
52. rd line treatment in advanced ovarian cancer (OVCA): An analysis of 744 patients (pts) treated with paclitaxel, docetaxel or high dose epirubicin. Proc Am Soc Clinic Oncol 1997; 16:254a (Abstr 1265).
53. Hoskins P, Tu D, James K, et al. Factors predictive of survival after first relapse or progression in advanced epithelial ovarian carcinoma: A prediction tree analysis derived model with test and validation groups. Gynecol Oncol, in press.
54. Colombo N, Marzola M, Parma G et al. Paclitaxel vs. CAP in recurrent platinum sensitive ovarian cancer. A randomized phase II study. Proc Am Soc Clin Oncol 1996; 15: 279 (Abstr).